Fresenius Net Working Capital vs Short Term Debt Analysis
FMS Stock | USD 25.08 0.21 0.84% |
Fresenius Medical financial indicator trend analysis is much more than just examining Fresenius Medical Care latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fresenius Medical Care is a good investment. Please check the relationship between Fresenius Medical Net Working Capital and its Short Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Net Working Capital vs Short Term Debt
Net Working Capital vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fresenius Medical Care Net Working Capital account and Short Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Fresenius Medical's Net Working Capital and Short Term Debt is -0.17. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Fresenius Medical Care, assuming nothing else is changed. The correlation between historical values of Fresenius Medical's Net Working Capital and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Fresenius Medical Care are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Net Working Capital i.e., Fresenius Medical's Net Working Capital and Short Term Debt go up and down completely randomly.
Correlation Coefficient | -0.17 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Working Capital
Short Term Debt
Most indicators from Fresenius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fresenius Medical Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Fresenius Medical's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.13 in 2025, whereas Selling General Administrative is likely to drop slightly above 2.2 B in 2025.
2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 5.3B | 4.9B | 4.8B | 3.8B | Total Revenue | 19.4B | 19.5B | 19.3B | 11.7B |
Fresenius Medical fundamental ratios Correlations
Click cells to compare fundamentals
Fresenius Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fresenius Medical fundamental ratios Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Common Stock Shares Outstanding | 294.3M | 586.1M | 586.5M | 586.8M | 674.9M | 607.5M | |
Total Assets | 31.7B | 34.4B | 35.8B | 33.9B | 33.6B | 19.3B | |
Short Long Term Debt Total | 12.4B | 13.3B | 13.2B | 12.1B | 11.0B | 6.5B | |
Other Current Liab | 3.0B | 3.0B | 3.1B | 3.2B | 3.1B | 1.9B | |
Total Current Liabilities | 6.2B | 7.3B | 6.5B | 6.1B | 5.7B | 3.7B | |
Total Stockholder Equity | 12.3B | 12.7B | 14.0B | 13.6B | 14.6B | 8.0B | |
Property Plant And Equipment Net | 4.1B | 8.6B | 8.3B | 7.5B | 7.3B | 7.6B | |
Net Debt | 11.3B | 11.8B | 11.9B | 10.7B | 9.8B | 5.8B | |
Retained Earnings | 10.3B | 10.8B | 10.7B | 10.9B | 11.3B | 11.8B | |
Accounts Payable | 827.4M | 857.5M | 951.6M | 885.1M | 984.3M | 554.3M | |
Cash | 1.1B | 1.5B | 1.3B | 1.4B | 1.2B | 616.0M | |
Non Current Assets Total | 24.4B | 26.4B | 27.6B | 25.2B | 25.6B | 14.3B | |
Non Currrent Assets Other | 4.8B | 1.2B | 702.5M | 681.8M | 720.0M | 676.8M | |
Cash And Short Term Investments | 1.2B | 1.6B | 1.5B | 1.6B | 1.3B | 681.1M | |
Net Receivables | 3.6B | 3.6B | 3.7B | 3.6B | 3.4B | 2.6B | |
Liabilities And Stockholders Equity | 31.7B | 34.4B | 35.8B | 33.9B | 33.6B | 19.3B | |
Non Current Liabilities Total | 13.2B | 13.1B | 13.8B | 13.0B | 12.1B | 7.4B | |
Inventory | 1.9B | 2.0B | 2.3B | 2.2B | 2.1B | 1.1B | |
Other Current Assets | 455.7M | 708.0M | 725.8M | 1.3B | 1.1B | 680.5M | |
Other Stockholder Equity | 4.0B | 2.9B | 3.4B | 3.4B | 3.3B | 3.0B | |
Total Liab | 19.4B | 20.4B | 20.3B | 19.1B | 17.8B | 11.1B | |
Property Plant And Equipment Gross | 8.2B | 4.3B | 4.2B | 17.9B | 18.8B | 17.9B | |
Total Current Assets | 7.3B | 8.0B | 8.2B | 8.7B | 7.9B | 5.0B | |
Accumulated Other Comprehensive Income | (2.2B) | (1.3B) | (388.5M) | (975.2M) | (328.5M) | (345.0M) | |
Short Term Debt | 1.7B | 2.6B | 2.0B | 1.6B | 1.2B | 1.1B | |
Intangible Assets | 1.4B | 1.5B | 1.5B | 1.4B | 1.4B | 1.7B | |
Common Stock | 304.4M | 292.9M | 293.0M | 293.4M | 337.4M | 261.0M | |
Current Deferred Revenue | 606.3M | 518.0M | 105.7M | 85.8M | 82.2M | 78.1M | |
Other Liab | 2.1B | 2.5B | 2.4B | 2.7B | 3.1B | 3.2B | |
Other Assets | 1.1B | 1.2B | 1.1B | 507.5M | 427.8M | 502.4M | |
Long Term Debt | 6.8B | 6.6B | 7.2B | 7.0B | 6.3B | 5.8B | |
Property Plant Equipment | 8.2B | 8.6B | 8.3B | 7.5B | 7.3B | 4.0B | |
Good Will | 13.0B | 14.4B | 15.8B | 14.7B | 15.2B | 14.4B | |
Short Term Investments | 161.7M | 159.2M | 187.8M | 154.4M | 163.1M | 148.2M | |
Net Tangible Assets | (3.5B) | (3.1B) | (3.1B) | (3.3B) | (3.8B) | (4.0B) | |
Long Term Investments | 761.1M | 786.9M | 773.7M | 1.3B | 1.4B | 911.9M | |
Short Long Term Debt | 1.1B | 1.9B | 1.4B | 944.6M | 577.4M | 548.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fresenius Stock Analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.